Delivering Cures for Cancer is dedicated to fast tracking the availability of cures for cancer using new screening technologies and cancer-targeting, nanomedicine based delivery systems, which increases the effectiveness of drugs and eliminates toxic side effects, advancing the standard of cancer care for all. Delivering Cures for Cancer, was formerly known as The Paula Shore Sari Fox (PSSF) Foundation.
Behind Delivering Cures for Cancer: Human Interest Story Leads to Trailblazing Advances in Medical Technology
Paula Shore and Sari Fox were kind, loving and loyal mothers and wives. As matriarchs, they led by example, always put family first, and were active in their communities. They were vibrant, outgoing, and considered dear friends by all within their inner circles. They were trusted confidants, and their opinion was highly-valued. Meticulous, with sharp instincts, keen logic, and quick wit, Paula and Sari were a true tour de force. Their lives were filled with love, friendship and happiness, but ended far too soon.
[accordion openfirst=false clicktoclose=true tag=h6]
[accordion-item title=”Dr. Ronald Shore, Founder”]
Dr. Ronald Shore is an acclaimed dermatologist practicing in Montgomery County, Maryland. He was born and raised in Canada, where he attended and graduated from the University of Saskatchewan School of Medicine as a Doctor of Medicine with Great Distinction. He received multiple accolades during his academic career, including 11 academic scholarships. Following medical school, Dr. Shore completed an internship and fellowship in medicine at Johns Hopkins Hospital and a residency in dermatology at the University of Pennsylvania. Upon graduating, he relocated to Maryland in 1977 and has been in private practice in the field of dermatology ever since.
Throughout his long and illustrious career, he has enjoyed a multitude of medical accomplishments, including contributing to the teaching program for dermatology residents and medical students at Johns Hopkins for over 30 years, authoring over 40 medical papers, creating or co-creating several diagnostic tests, lecturing internationally, and hosting courses at Annual Meetings of the American Academy of Dermatology. In addition, Dr. Shore was approached by Johnson and Johnson to develop a new treatment for psoriasis based on his previous research. With a long-time interest and passion for promoting skin cancer screenings, Dr. Shore’s serial screening program for melanoma, which has been in existence for over 20 years, has received worldwide attention and is believed to be the longest running cancer screening program to achieve 100% survival of program participants.
In 2012, Dr. Shore contributed to the development of the “Paula’s Test”, a revolutionary new blood test that screens for lung cancer. The test, which was developed by the biotech company 20/20 GeneSystems, was named after Dr. Shore’s wife, who died from lung cancer.
In 2013 Dr. Shore co-founded Delivering Cures for Cancer to honor his late wife.
[accordion-item title=”Dr. Joseph Fox, Founder”]
Dr. Joseph Fox is a renowned surgeon and board-certified podiatrist maintaining a private practice in New York. Dr. Fox attended medical school at New York College of Podiatric Medicine, completed postgraduate work at Johns Hopkins School of Public Health and Hygiene, and completed his residency through the Maryland Hospital Network Podiatry Residence Program. Dr. Fox has had over 35 years of experience in both his medical practice and teaching the surgical residents in several major New York City Hospitals. He is currently on staff at Weil-Cornell New York-Presbyterian Hospital as a clinical attending in the Department of Surgery. In addition, he was acknowledged by New York City Mayor Giuilani as a first responder on 9/11 and serves as the podiatry consultant to organizations such as the United Nations and several ballet and theatre companies – honors shared only by a small elite group of medical professionals around the world. He has also been recognized on an international level for his work in establishing worldwide clinics that specialize in wound care and diabetic foot care.
In addition to his pioneering work in the field of podiatry, Dr. Fox has devoted a great deal of his time and energy to cancer-focused efforts. In large part, this passion has stemmed from the untimely death of his wife, Sari, who battled ovarian cancer for seven years. Her courageous struggle prompted Dr. Fox to fight for more effective treatment of the disease. For instance, he vigorously advocated for the use of the drug Avastin – which was used primarily for the treatment of colon cancer – to be used in the treatment of his wife’s ovarian cancer. He also has contributed to and affiliated himself with the Angiogenesis Foundation and supports the LifeIce organization, both of which promote healthy eating habits and combating cancer.
In 2013, Dr. Fox co-founded Delivering Cures for Cancer to honor his late wife.
[accordion-item title=”Dr. Esther Chang, Principal Advisor”]
Dr. Esther Chang is a member of the Departments of Oncology and Otolaryngology at the Lombardi Comprehensive Cancer Center of Georgetown University Medical Center. Before joining Georgetown University, Dr. Chang held positions in the National Cancer Institute as a Cancer Expert, as a professor in the Department of Surgery at Stanford University, and as a professor in the Departments of Pathology and Surgery at the Uniformed Services University of Health Sciences. Currently, she is serving as the President of the American Society for Nanomedicine and is also an Executive Board Member of the International Society for Nanomedicine (ISNM) in Basel.
Dr. Chang is the founding scientist of, as well as a Senior Consultant, for SynerGene Therapeutics, Inc. Dr. Chang’s research effort focuses primarily on the molecular mechanisms of carcinogenesis and in translating this basic information into new clinical modalities. She believes that delineation of the roles of various genetic factors, transforming oncogenes and tumor suppressor genes, in the multistep process of tumor formation, is the key to improved diagnosis and effective therapy of cancer.
Dr. Chang has been a pioneer and a major contributor to understanding genetic influences on both the development and suppression of malignant tumors, as well as to understanding the molecular basis of tumors’ resistance to radiation and chemotherapy. She was the first to identify human versions of a mouse viral oncogene and to demonstrate the role of these “ras oncogenes” in carcinogenesis. As determined by Current Contents, two of Dr. Chang’s seminal papers on this topic are among the top 100 most-cited publications in Life Sciences (1982-84). Her research group also was the first to demonstrate, simultaneously with another, that a mutated p53 gene (which has since been identified as one of the most frequently altered genes in human cancer) is the primary genetic defect in a cancer-prone family with Li-Fraumeni Syndrome. Dr. Chang’s publication on this finding is among the top 10 most-cited publications in Medicine (1991-92), according to Science Watch. One of Dr. Chang’s publications was selected as the recipient of the 2010 Herbert M. Stauffer Award for Best Basic Science paper in early cancer diagnosis.
Dr. Chang’s research on the application of nanotechnology to cancer therapy, diagnosis and prevention was recognized in Science News Magazine as among the most promising efforts in the field. Most recently, her research group has been evaluating the combination of systemic, tumor-targeted gene therapy and more conventional radiotherapy or chemotherapy for treatment of cancers. These nanotechnology-based therapeutic approaches have been shown to systemically deliver the p53 gene, homing specifically, not only to the primary tumor, but also to the metastases, which are the ultimate cause of so many cancer deaths. This nanodelivery system, carrying the human tumor suppressor gene p53, has just completed a Phase Ia clinical trial as a single agent. The agent has been shown to be safe with anti-cancer effect. A Phase Ib combination trial with p53 and Docetaxel is currently ongoing. A Phase Ib/II trial with p53 and gemcitabine in patients with advanced pancreatic cancer has just received FDA approval.
Another human tumor suppressor gene RB94, as a payload delivered by the same nano-system, has demonstrated marked anti-tumor efficacy in pre-clinical studies. A Phase I Safety Trial of the agent is currently ongoing. The nanodelivery system represents a much broader nanotechnology platform in that the payload is not only limited to gene medicine, but also is applicable to siRNAs/miRNAs, antisense oligonucleotides, imaging agents, small molecules, and chemotherapeutic agents.
Dr. Chang has over 130 publications, is the inventor of 100 issued patents, and has served as a member of a number of scientific advisory boards for the National Cancer Institute, NASA, the US Military Cancer Institute, and the Department of Energy. Her scientific findings have been published in prominent journals including Nature, Science, Cancer Research, Cell, Human Gene Therapy, among others. She also has dedicated much time to the education of undergraduate, graduate and medical students. Dr. Chang has held peer reviewed grants from the NIH for more than 29 years without interruption. She is the Principal Advisor to Delivering Cures for Cancer, which is dedicated to accelerating the availability of a cure for cancer using cancer-targeted, nanomedicine-based delivery systems.
[accordion-item title=” Professor Michio Kaku, Spokesman”]
Professor Michio Kaku is an American theoretical physicist, futurist, and popularizer of science. Kaku is a professor of theoretical physics at the City College of New York and CUNY Graduate Center. He has written several books about physics and related topics, has made frequent appearances on radio, television, and film, and writes online blogs and articles. He has written three New York Times best sellers: Physics of the Impossible (2008), Physics of the Future (2011), and The Future of the Mind (2014). Kaku has hosted several TV specials for the BBC, the Discovery Channel, the History Channel, and the Science Channel.
Kaku has appeared in many forms of media and on many programs and networks, including Good Morning America, The Screen Savers, Larry King Live, 60 Minutes, Imus In The Morning, Nightline, 20/20, Naked Science, CNN, ABC News, CBS News, NBC News, Al Jazeera English, Fox News Channel, The History Channel, Conan, The Science Channel, The Discovery Channel, TLC, Countdown with Keith Olbermann, The Colbert Report, The Art Bell Show and its successor, Coast to Coast AM, BBC World News America, The Covino & Rich Show, Head Rush, Late Show with David Letterman, and Real Time with Bill Maher. Kaku is popular in mainstream media because of his knowledge and his accessible approach to presenting complex subjects in science. While his technical writings are confined to theoretical physics, his public speaking and media appearances cover a broad range of topics, from the Kardashev scale to more esoteric subjects such as wormholes and time travel.
[accordion-item title=”Janine Shore, CEO”]
Janine Shore wants to make the best use of her time on this planet. Having watched her mother suffer through cancer treatment, Ms. Shore, a driven entrepreneur and former entertainment industry executive, knew she could do more. Even after receiving an international distribution deal for her award-winning films and completing a contract with Universal Records producing music videos for MTV, she resigned from a promising career with a skyrocketing trajectory. Since 2012, Ms. Shore has been dedicated to advancing the standard of cancer care.
Ms. Shore, who holds a B.S. in Communications from Boston University, spends much of her time in her role as CEO of Delivering Cures for Cancer, a non-profit organization whose mission is to deliver trail-blazing, cutting-edge early detection screening protocols and pioneering treatments for advanced cancer. In addition to managing a thriving cosmetic dermatology practice, Ms. Shore works tirelessly with governing agencies, biotech companies, and others invested in curing cancer. She has an extensive knowledge of the medical field and cancer treatments, and understands firsthand the challenges associated with treating cancer, the obstacles researchers face in employing new therapies, and the implications for the country’s healthcare system.
Under Ms. Shore’s leadership, Delivering Cures for Cancer is actively working to further fund the pioneering research by world-renowned Nanotechnologist and Oncologist, Dr. Esther Chang, of Georgetown University Lombardi Cancer Center. Dr. Chang is currently President of the American Society for Nanomedicine, and has developed a treatment for advanced stage cancers that utilizes tumor-targeted nanomedicine technology This treatment delivers encapsulated drugs and tumor suppressing genes to cancer cells only, without affecting the body’s healthy cells, tissue, and organs. Dr. Michio Kaku, renowned theoretical physicist, New York Times best-selling author and media consultant coined the term “the Holy Grail of Cancer Research” to describe Dr. Chang’s Nanomedicine Delivery System.
This treatment increases the effectiveness of drugs, corrects damaged genes, passes the blood brain barrier, and eliminates the toxic side effects associated with traditional chemotherapy. In current, on-going Phase II FDA clinical trials, employing this therapy has resulted in apoptosis (programmed cancer cell death), and a reduction in size of primary tumors and metastases. Thus, making inoperable cancers operable and has yielded unparalleled published results.
As CEO of Delivering Cures for Cancer, Ms. Shore is frequently invited to participate in speaking engagements, where she presents this research, and was a keynote speaker at the 2018 NASA Goddard Safety Awareness Week. She advocates a new way of thinking about cancer treatment and promotes combining current therapies with the latest technologies to make treatments more effective, humane, and economical. Ms. Shore is looking to this new research model that brings to light promising therapies to cure cancer, save lives and preserve families.
Paula Shore and Sari Fox: The Battles with Cancer that Led to the Delivering Cures for Cancer Foundation
Paula was the picture of perfect health. A petite woman, she ate right, exercised regularly, and was in amazing shape. It didn’t cross anyone’s mind that she could be plagued with sickness, but in February of 2005, everything changed. Paula noticed a lump on her back, which looked like a cyst. The lesion was biopsied, and the worst was revealed: it was advanced metastatic cancer. Further tests indicated the cancer had originated in her lungs, which was a terrible shock to Paula and her family, as she had smoked only for a short time early in her life, and had quit nearly 22 years earlier. Paula was entered into a promising chemotherapy study, but the optimistic outlook quickly turned sour as the cancer continued to spread. A second chemotherapeutic agent did no better, and instead of helping her combat the disease, it destroyed her white blood cells. She then entered a new vaccine study at NIH in Bethesda, MD but became so weak, she had to be hospitalized. The deterioration was dramatic and rapid. She lost a great deal of weight, she lost her hair, and she became so sensitive to light and sounds that she could no longer enjoy simple things like watching TV or going outside. She couldn’t eat, she couldn’t walk, and eventually, she lost her vision and her ability to talk because the cancer had spread to her brain. The effects were devastating and unfathomable.
And for Paula’s family, watching her suffer was unbearable. Her husband Ron had contacted 100 oncologists around the world to find a treatment and sent samples of his wife’s cancer cells to them to be tested for potentially helpful drugs, but to no avail. In an effort to save his wife, he spent endless hours studying articles on cancer research and alternate treatments. He lost 30 pounds and was in a devastated state.
It was equally painful and traumatic for Paula’s daughters to watch their mother deteriorate and endure the agony she dealt with on a daily basis. They felt helpless, cheated, and overwhelmed with grief. The disease had come out of nowhere, and because of her rapid deterioration, there simply wasn’t enough time to cope. Just weeks after preparing letters to all of her closest friends, thanking them for the many years of friendship they had shared and reassuring her family that it would be OK, Paula lost her fight on July 18, 2005 at the age of 56.
In spite of her tremendous suffering, Paula was the epitome of bravery. Never once did she ask the question, “Why me?”. Instead, she encouraged her family and faced death with dignity and strength, but she did have a dying wish: the wish was that one day, a cure for the dreadful disease that had stolen her life would be found so that others would not have to suffer like she did and endure the same fate.
In 2003 Sari was diagnosed with Stage IIIC ovarian cancer, and began a 7-year battle that included continual chemotherapy, several surgeries and many complications. Sari fearlessly pursued many different treatments: neoadjuvant therapy with experimental agents; debulking surgeries; and the administration of 18 different chemotherapy drugs. She called the chemotherapy her “toxic cure.”
Then, in 2008, Sari experienced sudden seizures that led to the discovery of an unusual metastasis of her ovarian cancer to the brain. She had immediate surgery to remove the tumor, and despite a long road to recovery, with speech and physical therapy, she persevered and returned to living life once again.
Two years later, however, in early summer 2010, Sari became noticeably weaker and experienced difficulty with her speech. An MRI revealed several inoperable brain metastases. Still wanting to fight this disease, she elected to have radiation in hopes of seeing a positive result.
Unfortunately, Sari and her family eventually ran out of options. Sari’s ability to fight her disease had weakened due to complications, and all that was left for the family to do was to find a way to make her as comfortable as possible. Sari’s husband and d
aughters, respected her decision to remain at home, and not be hospitalized. Sadly, in early September 2010, Sari passed away at home and in the company of those that loved her most. Through her courageous fight, Sari will forever be remembered as an amazing, brilliant, beautiful, wife ,and mother.
A Plea from the Daughters
We’ve all read articles or seen programs on TV about the devastating effects of cancer on a person, but until you’ve actually witnessed a family member suffer from cancer, you can’t ever truly understand just how devastating the disease truly is. There is simply nothing that can prepare you. Quite blatantly, it’s unfathomable. Even in spite of the staggering statistics on the number of lives that are affected and taken by cancer each year, many people live in the, “That’s really sad, but that will never happen to my family or me” mentality.
We know that mentality all too well because that’s how we thought. We never could have imagined that cancer would affect our families. We never expected to have to watch our mothers suffer the incredibly intense pain they did and deteriorate in the horrifically dramatic fashion we witnessed. And we never could have dreamed they would have been stolen away from us and we’d be left to face our lives without them. But that is exactly what became our reality.
Like our fathers, we didn’t want what our mothers went through to be in vain. That’s what the Delivering Cures for Cancer Foundation is all about. It is our deepest hope that the information, research, and treatment options available through the Foundation will help prevent others from experiencing what they did. Our goal is that this organization will make a change – a real change – to cancer treatment that will not only eliminate the barbaric process cancer patients currently have to endure, but save their lives, and, in effect, preserve their families.
Change and change for the better. That’s what we are promoting. Change to the treatments that are available to cancer patients — treatments that will target solely cancer cells and not fill their bodies with toxins; treatments that will not cause them to lose their hair; treatments that will not devastate their already weakened bodies even more. But we need your help to continue our research so that these treatments can be made available to people who desperately need them. Maybe that person is your friend. Maybe that person is a family member. Maybe that person is your mother. Please help us spread
this message for her sake.
Janine Shore, CEO
Background on the Nanomedicine Delivery System
Thanks to the pioneering work of world-renowned Nanotechnologist and Oncologist Dr. Esther Chang of Georgetown University, even those with advanced stage cancers stand a fighting chance of surviving. Dr. Chang has developed a treatment for advanced stage cancers that utilizes nanomedicine technology. What sets this treatment apart from any other treatment is that it delivers drugs specifically to cancer cells WITHOUT affecting normal cells. In animal studies, this treatment cured ALL OF THE MAJOR CANCERS without the typical toxic side effects that are so prevalent with traditional treatments (hair loss, severe nausea, etc.). Moreover, while drugs used to treat common side effects caused by current treatments typically cost thousands of dollars, with Dr. Chang’s treatment, no additional drugs would likely be required, thereby saving an inordinate amount of money. And this treatment could be made available soon. The only major obstacle standing in the way is the completion of FDA studies . . . which requires additional funding.
How does Tumor-Targeted Nanomedicine Work?
Dr. Chang’s nano-delivery system uses minute nanoparticles that not only accurately locate and attach to cells in primary tumors, but also target and attach to cancer cells that have metastasized to other parts of the body. The therapeutic agents carried by the nanoparticles are then transferred into the cancer cells, killing them. This tumor targeted delivery system not only greatly increases treatment effectiveness, but also enables healthy cells to be spared and eliminates harmful side effects.
New Early Screening Test for Cancer
Today, there is an early detection test that can identify lung cancer even when no symptoms are present! The test was developed by 20/20 GeneSystems, Inc. in Rockville MD, and is known as the PAULA’s Test. The name serves both as an acronym indicating the nature of the test (i.e. Protein Assays Using Lung Cancer Analytes), and to honor one of the Foundation’s namesakes, Paula Shore. Individuals or physicians interested in having the test may obtain additional information at www.paulastest.com.
Each year, 160,000 Americans die of lung cancer. Paula Shore was among them. She had a healthy lifestyle, and had undergone the screening tests appropriate for her gender and age. Unfortunately, she still contracted lung cancer. At the time, in 2005, there were no blood tests available to detect her cancer early when surgery could have saved her life. Paula Shore’s legacy lives on through groundbreaking new cancer screenings for early detection. It has been demonstrated that blood test biomarkers have detected evidence of lung cancer long before it was evident on x-ray studies.
If performed on patients annually, PAULA’s Test could detect cancer early, resulting in much more favorable survival rates.”
Early detection is something Dr. Shore has been advocating for a quarter of a century. At his dermatology practice, he has persuaded high risk patients to come in for check-ups every six months. The results? In over 25 years, not one person in the program has died from skin cancer or even had a close call:
The Skin Check Program – 1992 to Present
Over 20,000 skin examinations performed
Over 3,000 skin cancers detected
Over 100 melanomas detected
But NO DEATHS due to any skin cancers
Details of his program have been published in the Journal of Drugs in Dermatology: Drugs-Devices-Methods. 2011;10(3):244-252) and reported at major dermatology meetings. This article (in PDF) is provided with compliments by the Journal of Drugs in Dermatology (JDD).